Keeping Track: First COVID Vaccine BLA Kicks Off; Oncology Submissions From Hutchmed, Takeda And Shorla
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs
Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.
US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
Premature PRV: US FDA Mistakenly Announces Voucher Award For Enzyvant Ahead Of Approval
Congenital athymia treatment Rethymic (RVT-802) is still under FDA review, with an 8 October user fee goal date, but FDA announced the regenerative medicine product had earned a rare pediatric disease priority review voucher; agency says the notice was published in error and will be withdrawn.